In short: One of the three already-public microreactor names, at a $625 million market cap — and the only public one the article's investor voice actually owns: "Segra has invested in Valar Atomics and Terra Innovatum." Not an Army selection, so it gets the sector catalyst without the contract; the endorsement is the specialist's capital, against a cap far below the $1.9B–$6B private marks.
Terra Innovatum is one of only three microreactor companies you can actually buy on a public exchange, and at roughly $625 million it is valued at a fraction of the private startups — Valar Atomics is marked at $6 billion, Radiant at $1.9 billion. Normally private companies trade at a discount to public ones; here it is the reverse, which is either an opportunity or a warning about what the private marks mean.
What distinguishes it in this article is one sentence: Segra Capital, the nuclear-focused hedge fund whose manager supplies all the skeptical analysis in the piece, has invested in it. That is a specialist committing capital, and it carries more weight than a valuation, because the same manager spends several paragraphs explaining why most microreactor deployments will not make economic sense.
What it does not have: it was not one of the Army's five selections, and it is not named among the companies that reached criticality this year. So it gets the sector's tailwind and an informed backer, without the contract or the technical milestone that de-risk the others.
Nothing matches this filter.
Verbatim excerpts from the public transcripts (auto-pulled at each mention's timestamp, lightly cleaned). Timestamps link into the video; "source page" opens that commentator's full analysis at this row. Click a mention's header line to expand it (one open at a time). For personal study — not investment advice.